Amgen on Tuesday posted quarterly financial results that beat Wall Street expectations as a 9% increase in product sales ...

Fifteen of the biotechnology company’s products delivered at least double-digit sales growth in the second quarter.

Amgen (NASDAQ:AMGN) surpasses Q2 earnings and revenue expectations with a 9.4% revenue growth. Read more here.

Biotech company Amgen (NASDAQ:AMGN) reported Q2 CY2025 results , with sales up 9.4% year on year to $9.18 billion. The ...

Non-GAAP earnings per share for Q2 2025 beat estimates by 14.0%, rising to $6.02 (non-GAAP) and up 21% year over year (non-GAAP). Revenue increased 9% to $9.2 billion, exceeding analyst expectations ...

Amgen Inc (NASDAQ:AMGN) shares held near flat in after-hours trading Tuesday despite posting better-than-expected quarterly ...

Amgen (AMGN) to announce Q2 earnings with expected 6% growth in EPS & revenue. Key acquisitions bolster rare disease pipeline ...

The stock slipped 3.5% postmarket after the chip maker reported adjusted earnings per share in line with estimates.

Analysts estimate that Amgen will report an earnings per share (EPS) of $5.26. The announcement from Amgen is eagerly anticipated, with investors seeking news of surpassing estimates and favorable ...

(RTTNews) - Amgen Inc. (AMGN) announced that it swung to profit in its first quarter of 2025 from a loss last year, helped by higher revenues and an unrealized gain on its BeiGene, Ltd. equity ...